Drugs & Targets FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC May 22, 2026Vol.52 No.20
Podcast The Cancer History Project debuts first de novo book; meanwhile, FDA snafus continue May 20, 2026
FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applicationsCritics say policies clear the way for major tobacco companies to enter fruit-flavored vape market May 15, 2026Vol.52 No.19By Sara Willa Ernst
Regulatory News After a year-long reign over tumult at FDA, Makary heads for the exitFruit-flavored e-cigs were the final blow for the commissioner May 15, 2026Vol.52 No.19By Claire Marie Porter
Drugs & Targets FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML May 15, 2026Vol.52 No.19
Drugs & Targets Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program May 15, 2026Vol.52 No.19
Drugs & Targets FDA clears AI digital pathology risk stratification tool in breast cancer May 15, 2026Vol.52 No.19
Podcast Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now) May 13, 2026
